Optimising Supply Chain for Cellular Platform

Cell and gene therapy supply tracking and orchestration systems software developer TrakCel and CDMO WuXi AppTec Advanced Therapies, have signed a collaborative agreement to accelerate the seamless delivery of advanced therapy treatments to mutual customers.

The two companies will leverage configured manufacturing module in TrakCel’s software, based around WuXi’s current standard operating procedures and preferred workflows. The design of this module will be based on the companies’ long and extensive working relationship. WuXi AppTec Advanced Therapies was the first CDMO to use Cardiff-based TrakCel’s software and its Philadelphia, PA site currently has a greater number of users than any other facility in the supply chain. The resultant pre-built manufacturing module will shorten the time and costs associated with deploying an end-to-end solution to both companies’ mutual clients.

 “As one of the first CDMOs to use TrakCel’s software and the supply chain partner with more users than any other facility, WuXi AppTec Advanced Therapies is well placed to collaborate with TrakCel to identify a more efficient way of working together. It is the latest development in TrakCel’s formation of an international partner ecosystem of connected and complementary cell and gene therapy service providers. This partner ecosystem as a result now includes a commercial scale, third party manufacturing company,” said Ravi Nalliah, CEO, TrakCel. “The TrakCel partnership with WuXi AppTec Advanced Therapies will enable both companies to move towards increased standardization and improved delivery of these innovative treatments to patients around the world.”  

“We are pleased to establish a collaborative agreement with TrakCel to support customers that seek to promote streamlining personalized therapies from specimen connections to manufacturing,” said Felix Hsu, Senior Vice President and Global Head of WuXi AppTec Advanced Therapies. “With our leading integrated manufacturing and testing services, we believe we can bring even more speed, reliability and security to an already complex manufacturing and supply chain. We are committed to helping our partners deliver more innovative therapies to patients and the market sooner.”